89 related articles for article (PubMed ID: 11596475)
1. [Development of transgenic animal models for Alzheimer's disease].
Watanabe N; Tabira T
No To Shinkei; 2001 Sep; 53(9):809-20. PubMed ID: 11596475
[No Abstract] [Full Text] [Related]
2. Mechanisms of memory loss in Abeta and tau mouse models.
Ashe KH
Biochem Soc Trans; 2005 Aug; 33(Pt 4):591-4. PubMed ID: 16042551
[TBL] [Abstract][Full Text] [Related]
3. Metallothionein-I and -III expression in animal models of Alzheimer disease.
Carrasco J; Adlard P; Cotman C; Quintana A; Penkowa M; Xu F; Van Nostrand WE; Hidalgo J
Neuroscience; 2006 Dec; 143(4):911-22. PubMed ID: 17027170
[TBL] [Abstract][Full Text] [Related]
4. A decade of modeling Alzheimer's disease in transgenic mice.
McGowan E; Eriksen J; Hutton M
Trends Genet; 2006 May; 22(5):281-9. PubMed ID: 16567017
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein E and Alzheimer's.
van Bockxmeer FM
Nature; 1995 May; 375(6529):285. PubMed ID: 7753191
[No Abstract] [Full Text] [Related]
6. Biological transgenic mouse models of Alzheimer's disease.
Crews L; Rockenstein E; Masliah E
Handb Clin Neurol; 2008; 89():291-301. PubMed ID: 18631753
[No Abstract] [Full Text] [Related]
7. Do axonal defects in tau and amyloid precursor protein transgenic animals model axonopathy in Alzheimer's disease?
Götz J; Ittner LM; Kins S
J Neurochem; 2006 Aug; 98(4):993-1006. PubMed ID: 16787410
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis of brain tissue from an Alzheimer's disease mouse model by two-dimensional difference gel electrophoresis.
Sizova D; Charbaut E; Delalande F; Poirier F; High AA; Parker F; Van Dorsselaer A; Duchesne M; Diu-Hercend A
Neurobiol Aging; 2007 Mar; 28(3):357-70. PubMed ID: 16519965
[TBL] [Abstract][Full Text] [Related]
9. [Experimental models in Alzheimer's disease].
Manzano S; González J; Marcos A; Payno M; Villanueva C; Matías-Guiu J
Neurologia; 2009 May; 24(4):255-62. PubMed ID: 19603296
[TBL] [Abstract][Full Text] [Related]
10. Truncated tau at D421 is associated with neurodegeneration and tangle formation in the brain of Alzheimer transgenic models.
Zhang Q; Zhang X; Sun A
Acta Neuropathol; 2009 Jun; 117(6):687-97. PubMed ID: 19190923
[TBL] [Abstract][Full Text] [Related]
11. Accelerated amyloid deposition, neurofibrillary degeneration and neuronal loss in double mutant APP/tau transgenic mice.
Ribé EM; Pérez M; Puig B; Gich I; Lim F; Cuadrado M; Sesma T; Catena S; Sánchez B; Nieto M; Gómez-Ramos P; Morán MA; Cabodevilla F; Samaranch L; Ortiz L; Pérez A; Ferrer I; Avila J; Gómez-Isla T
Neurobiol Dis; 2005 Dec; 20(3):814-22. PubMed ID: 16125396
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice.
Grueninger F; Bohrmann B; Czech C; Ballard TM; Frey JR; Weidensteiner C; von Kienlin M; Ozmen L
Neurobiol Dis; 2010 Feb; 37(2):294-306. PubMed ID: 19781645
[TBL] [Abstract][Full Text] [Related]
13. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau.
Shin RW; Ogino K; Shimabuku A; Taki T; Nakashima H; Ishihara T; Kitamoto T
Acta Neuropathol; 2007 Jun; 113(6):627-36. PubMed ID: 17431643
[TBL] [Abstract][Full Text] [Related]
14. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse.
Gordon MN; Holcomb LA; Jantzen PT; DiCarlo G; Wilcock D; Boyett KW; Connor K; Melachrino J; O'Callaghan JP; Morgan D
Exp Neurol; 2002 Feb; 173(2):183-95. PubMed ID: 11822882
[TBL] [Abstract][Full Text] [Related]
15. Multi-metric behavioral comparison of APPsw and P301L models for Alzheimer's disease: linkage of poorer cognitive performance to tau pathology in forebrain.
Arendash GW; Lewis J; Leighty RE; McGowan E; Cracchiolo JR; Hutton M; Garcia MF
Brain Res; 2004 Jun; 1012(1-2):29-41. PubMed ID: 15158158
[TBL] [Abstract][Full Text] [Related]
16. Impaired cell proliferation in the subventricular zone in an Alzheimer's disease model.
Rodríguez JJ; Jones VC; Verkhratsky A
Neuroreport; 2009 Jul; 20(10):907-12. PubMed ID: 19494789
[TBL] [Abstract][Full Text] [Related]
17. Indirubin-3'-monoxime rescues spatial memory deficits and attenuates beta-amyloid-associated neuropathology in a mouse model of Alzheimer's disease.
Ding Y; Qiao A; Fan GH
Neurobiol Dis; 2010 Aug; 39(2):156-68. PubMed ID: 20381617
[TBL] [Abstract][Full Text] [Related]
18. A tale about tau.
Ashe KH
N Engl J Med; 2007 Aug; 357(9):933-5. PubMed ID: 17761598
[No Abstract] [Full Text] [Related]
19. High dietary consumption of trans fatty acids decreases brain docosahexaenoic acid but does not alter amyloid-beta and tau pathologies in the 3xTg-AD model of Alzheimer's disease.
Phivilay A; Julien C; Tremblay C; Berthiaume L; Julien P; Giguère Y; Calon F
Neuroscience; 2009 Mar; 159(1):296-307. PubMed ID: 19135506
[TBL] [Abstract][Full Text] [Related]
20. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition.
Bales KR; Verina T; Dodel RC; Du Y; Altstiel L; Bender M; Hyslop P; Johnstone EM; Little SP; Cummins DJ; Piccardo P; Ghetti B; Paul SM
Nat Genet; 1997 Nov; 17(3):263-4. PubMed ID: 9354781
[No Abstract] [Full Text] [Related]
[Next] [New Search]
